Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Enanta Pharmaceuticals (ENTA) Receivables Refunds (2020 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Receivables Refunds for 6 consecutive years, with $24000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Receivables Refunds fell 99.93% year-over-year to $24000.0, compared with a TTM value of $24000.0 through Jun 2025, down 99.93%, and an annual FY2024 reading of $32.0 million, up 3.21% over the prior year.
  • Receivables Refunds was $24000.0 for Q2 2025 at Enanta Pharmaceuticals, down from $33.8 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $37.3 million in Q3 2021 and bottomed at $24000.0 in Q2 2025.
  • Average Receivables Refunds over 5 years is $28.9 million, with a median of $30.6 million recorded in 2021.
  • The sharpest move saw Receivables Refunds skyrocketed 185.68% in 2021, then plummeted 99.93% in 2025.
  • Year by year, Receivables Refunds stood at $28.8 million in 2021, then dropped by 0.17% to $28.7 million in 2022, then increased by 10.56% to $31.7 million in 2023, then increased by 2.24% to $32.4 million in 2024, then plummeted by 99.93% to $24000.0 in 2025.
  • Business Quant data shows Receivables Refunds for ENTA at $24000.0 in Q2 2025, $33.8 million in Q1 2025, and $32.4 million in Q4 2024.